These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 18579718)

  • 1. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
    Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
    J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
    Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
    J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
    Espinel-Ingroff A; Arendrup MC; Pfaller MA; Bonfietti LX; Bustamante B; Canton E; Chryssanthou E; Cuenca-Estrella M; Dannaoui E; Fothergill A; Fuller J; Gaustad P; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Meis JF; Moore CB; Ostrosky-Zeichner L; Pelaez T; Pukinskas SR; St-Germain G; Szeszs MW; Turnidge J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5836-42. PubMed ID: 24018263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
    Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
    J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
    Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
    J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
    Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskov A; Ramani R
    J Clin Microbiol; 2008 Jul; 46(7):2155-9. PubMed ID: 18463213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough invasive candidiasis in patients on micafungin.
    Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
    J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Moet GJ; Jones RN
    J Clin Microbiol; 2010 May; 48(5):1592-9. PubMed ID: 20335424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.
    Fleischhacker M; Radecke C; Schulz B; Ruhnke M
    Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):127-31. PubMed ID: 18057972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.
    Khan Z; Ahmad S; Joseph L; Chandy R; Theyyathel A
    J Chemother; 2011 Apr; 23(2):97-101. PubMed ID: 21571626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
    Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.